#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Granulomatosis with polyangiitis Thrombotic microangiopathy Neuroendocrine carcinoma of the skin Tourette's disorder Anti-HLA antibody test positive ROHHAD syndrome Brain injury Chondrodystrophy Myeloid leukaemia Synovial sarcoma recurrent Muscular dystrophy Osteopetrosis Hereditary hypophosphataemic rickets Chemical burn Neoplasm More trials…

    Learn about Rare Diseases

    Mantle cell lymphoma stage IV – Treatment Paroxysmal nocturnal haemoglobinuria – Diagnostics Chondrosarcoma metastatic – Basic Information Amyotrophic lateral sclerosis – Basic Information Mast cell activation syndrome – Trials in Disease Ocular melanoma – Treatment Optic glioma – Diagnostics Krabbe’s disease – Treatment Mucopolysaccharidosis III – Basic Information Pulmonary fibrosis – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    ISPAGHULA HUSK Tozorakimab Propofol Mocravimod Sitagliptin Ale.c04 Avapritinib Brimonidine Ibuprofen Lysine Tamsulosin Hydrochloride Trastuzumab Deruxtecan Neostigmine Methylsulfate Festuca Elatior Pollen Extract Relebactam 177LU-FAP-2286 Tinzaparin Pemetrexed ALXN1920 Oxybutynin Prilocaine More therapies…

    Learn about Your Condition

    Peripheral artery restenosis Hypophosphatasia Clostridium difficile colitis Uveal melanoma Lysosomal storage disorder Diabetic neuropathy Fallopian tube cancer Syphilis Affective disorder Myocardial infarction Critical illness Ocular melanoma Primary biliary cholangitis Colorectal cancer stage II Fontan procedure More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Paoli-Calmettes Cancer Centre

Institut Paoli-Calmettes Cancer Centre

2fm Blgrwphxi Dn Sxbieq Mhgpxxkadyy Bt 1noq Mujnvycvxz 1dvsoj Fjathd

Want to learn more about this study or check if you can participate? Contact us.

  • Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Abiraterone Acetate
    • Cabazitaxel
    • Enzalutamide
    Austria Belgium Denmark France Germany Greece +5

  • A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Goserelin
    • Triptorelin
    • Leuprorelin Acetate
    Austria Belgium Bulgaria Croatia Czechia Estonia +10

  • A Study of Saruparib for Patients with Metastatic Pancreatic Cancer with Homologous Repair Deficiency as First Treatment

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Adenocarcinoma pancreas
    Investigated Drugs:
    • Saruparib
    France

  • Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Cervix carcinoma recurrent
    • Endometrial adenocarcinoma
    • Cholangiocarcinoma
    Investigated Drugs:
    • Bemarituzumab
    Austria Belgium Bulgaria Czechia Denmark Finland +9

  • Study of JSB462 and lutetium (177Lu) vipivotide tetraxetan combination for adult men with PSMA-positive metastatic castration resistant prostate cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Investigated Drugs:
    • LUXDEGALUTAMIDE
    • Gozetotide
    • Lutetium (177Lu) Vipivotide Tetraxetan
    Austria Czechia France Germany Italy The Netherlands +1

  • Evaluating Sonrotoclax Alone and Combined with Zanubrutinib for Patients with Previously Untreated or Relapsed/Refractory Waldenström Macroglobulinemia

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Waldenstrom’s macroglobulinaemia
    • Waldenstrom’s macroglobulinaemia refractory
    Investigated Drugs:
    • N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
    • Zanubrutinib
    France Greece Italy Spain

  • Study Comparing Axatilimab to Best Available Therapy for Patients with Chronic Graft-Versus-Host Disease After Two or More Treatments

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Chronic graft versus host disease
    Investigated Drugs:
    • Axatilimab
    Austria Belgium Czechia Finland France Germany +8

  • Study on the Effectiveness of Bemarituzumab and FLOT Chemotherapy for Patients with Resectable Gastric and Gastroesophageal Junction Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Adenocarcinoma gastric
    Investigated Drugs:
    • Bemarituzumab
    • Docetaxel
    • Fluorouracil
    France

  • Study of Bleximenib with Drug Combination for Patients with Acute Myeloid Leukemia with KMT2A or NPM1 Alterations

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • BLEXIMENIB
    • JNJ-75276617
    • Idarubicin
    France Germany Italy Spain

  • Study on the Effects of Maplirpacept, Glofitamab, and Obinutuzumab in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma Not Eligible for Stem Cell Transplant

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • MAPLIRPACEPT
    • Glofitamab
    • Obinutuzumab
    France Germany Spain
Previous Page
1 … 22 23 24 25 26 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!